Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15339920 | 0.91 | PTPN1 (0.40) | PTPN1KCNN4TUBB1 | |
| SCHEMBL17528451 | 0.85 | PTPN1 (0.36) | PTPN1KCNN4TUBB1 | |
| SCHEMBL31166726 | 0.80 | ALOX5AP (0.35) | PTPN1 | |
| SCHEMBL1509940 | 0.77 | PTPN1 (0.32) | PTPN1KCNN4 | |
| SCHEMBL30065168 | 0.76 | PTPN1 (0.33) | PTPN1KCNN4TUBB1 | |
| SCHEMBL19617169 | 0.76 | PTPN1 (0.33) | PTPN1KCNN4TUBB1 | |
| SCHEMBL17527871 | 0.76 | L3MBTL1 (0.40) | TUBB1 | |
| SCHEMBL1509904 | 0.76 | PTPN1 (0.34) | PTPN1TUBB1 | |
| SCHEMBL24032199 | 0.76 | PTPN1 (0.41) | PTPN1KCNN4 | |
| SCHEMBL28296673 | 0.76 | PTPN1 (0.49) | PTPN1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| EP-2852589-A1 | TRIAZOLES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175215-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611735-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | PTPN1 2711/4885KCNN4 54/4885TUBB1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.